Amyotrophic Lateral Sclerosis (ALS) & Multiple Sclerosis (MS) Module 1 PDF

Document Details

FormidableEiffelTower

Uploaded by FormidableEiffelTower

University of South Florida College of Nursing

2021

Tags

amyotrophic lateral sclerosis multiple sclerosis neurological diseases medical conditions

Summary

This document provides an overview of Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), including their causes, symptoms, treatments and complications. It details important aspects of these neurological diseases and addresses considerations for nursing practice.

Full Transcript

AMYOTROPHIC LATERAL SCLEROSIS (ALS) & MULTIPLE SCLEROSIS (MS) Patho Cause Disease Course & Expected Findings Amyotrophic Lateral Sclerosis (ALS) • Chronic, Progressive, Neurodegenerative • NO CURE • Autoimmune disease? NO • Fatal? YES • Targets the CNS & Brain • Loss of voluntary movement control,...

AMYOTROPHIC LATERAL SCLEROSIS (ALS) & MULTIPLE SCLEROSIS (MS) Patho Cause Disease Course & Expected Findings Amyotrophic Lateral Sclerosis (ALS) • Chronic, Progressive, Neurodegenerative • NO CURE • Autoimmune disease? NO • Fatal? YES • Targets the CNS & Brain • Loss of voluntary movement control, weakness, (spasticity & flacidity) • Patients suffer from lack of physical ability • Also called Lou Gehrig’s Disease Multiple Sclerosis • Chronic, progressive, neurodegenerative • NO CURE • Autoimmune inflammatory disease? YES • Fatal? NO • Targets the brain & spinal cord (myelin sheath) • Demyelination of white matter leads to decreased flow of nerve impulses. • Patients suffer with more cognitive dysfunction than with ALS • Sx worse in extreme heat & cold, stress, infection fatigue, pregnancy • Remissions & Exacerbations Unknown (genetic, environmental?) Uncommon disease. Most die within 3-5 years when symptoms first start. Only about 10% of people with ALS survive for 10 or more years. Causes progressive muscle weakness and wasting. Clients lose the ability to speak, eat, move, and eventually breathe (paralysis of respiratory muscles). • Fatigue • Muscle atrophy (wasting away, including tongue) & Muscle weakness followed by spasticity and hyperactive reflexes • Twitching (fasciculations) of face and tongue • Dysarthria (uncoordinated or slurred speech) • Dysphagia (difficulty swallowing) • Stiff and clumsy gait Unknown No cure, progressive in severity. Over time, may progress to tetraplegia. Normal life expectancy. • Fatigue • Muscle spasticity • Blurred or double vision (diplopia) • Scotomas (patches of blindness in peripheral vision) • Uhthoff’s sign (temp bad vision commonly seen just after exertion or when they are exposed to heat) • Nystagmus, tinnitus • Pain or Paresthesia • Hypoalgesia ( sensitivity to pain) • Areflexic (flaccid) or spastic bladder •  sexual function • Intention tremors (when performing activity) • Gait changes NUR3225 Module 1: Neurological Updated 12/27/2021 MR 1 Risk Factors Labs & Diagnostics Meds Amyotrophic Lateral Sclerosis (ALS) • Abnormal reflexes More common in men, 40-60yo. Multiple Sclerosis No definitive test to confirm presence Diagnosis based on Medical history Neurological examination Symptoms Lab test to rule out other metabolic conditions ONLY FDA Approved Meds for ALS: • riluzole (Rilutek) – decreases glutamate, less death of brain cells. • Woman x2 greater risk, 20-50yo, often whites of Northern European ancestry • • • • • • • Complications & Nursing Care edaravone (Radicava) – Antioxidant, decreases free radicals & oxidative stress. • Death Anxiety r/t impending progressive loss of function leading to death • • NUR3225 Module 1: Neurological Updated 12/27/2021 MR CSF reveals elevated protein level, slight increase in WBC’s,  IgG MRI →plaques of the brain & spine Evoke potential testing (give stimulation & see if sense is decreased) Interferon beta-1a & beta 1b – Injectables, side effects: Flu-like sx Muscle relaxants – baclofen (avoid stopping abruptly d/t risk for seizure, hallucination, rhabdomyolysis), dantrolene (monitor liver values, AST/ALT), diazepam (Valium) benzodiazepine Medical Marijuana- decreases pain, stiffness, spasticity. (May cause increased cognitive decline & dizziness) Dalfampridine (Ampyra) Improves gait/walking Steroids - Dexamethasone (Decadron) used for relapses, must taper off, increased risk for infection. Assess for sensory & mobility issues Psychosocial support for: apathy, emotional lability, depression 2 Amyotrophic Lateral Sclerosis (ALS) Palliative care for symptom management at end of life – home health, EOL planning Psychosocial support/ Supportive care to promote optimal function Ineffective breathing pattern r/t compromised muscles of respiration Multiple Sclerosis • Encourage fluid intake to prevent UTI • Promote cognitive function • Eye patches for diplopia • Group care & treatments to promote energy conservation. • Exercise & stretching of involved muscles (Avoid fatigue & overheating) • SLP for swallow issues • Safety: assistive devices, skin precautions, rehab support PT/OT • Bowel & Bladder Training o Track voiding schedule o Gradually lengthen voiding schedule o Schedule toileting o Assist with restroom visits o Changes in diet o Medication modification o Pelvic floor exercises Did your patient? • Remain free of infection • Maintain optimal mobility & function • Maintain adequate visual acuity & cognition to function independently. Long, R., Havics, B., Zembillas, M., Kelly, J. & Amundson, M. (2019). Elucidating the end-of-life experience of persons With Amyotrophic Lateral Sclerosis. Holistic Nursing Practice, 33, 3-8. https://doi.org/10.1097/HNP.0000000000000301 Jeffery, D. & Fish, A. (2018). A journey with Amyotrophic Lateral Sclerosis. Journal of Christian Nursing, 35, 152-159. https://doi.org/10.1097/CNJ.0000000000000502 NUR3225 Module 1: Neurological Updated 12/27/2021 MR 3

Use Quizgecko on...
Browser
Browser